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Abstract 
Mycoplasma hyopneumoniae (M. hyopneumoniae) is one of the primary agents involved in the porcine respiratory 
disease complex, economically one of the most important diseases in pigs worldwide. The pathogen adheres to 
the ciliated epithelium of the trachea, bronchi, and bronchioles, causes damage to the mucosal clearance system, 
modulates the immune system and renders the animal more susceptible to other respiratory infections. The patho-
genesis is very complex and not yet fully understood. Cell-mediated and likely also mucosal humoral responses 
are considered important for protection, although infected animals are not able to rapidly clear the pathogen from 
the respiratory tract. Vaccination is frequently practiced worldwide to control M. hyopneumoniae infections and the 
associated performance losses, animal welfare issues, and treatment costs. Commercial vaccines are mostly bacterins 
that are administered intramuscularly. However, the commercial vaccines provide only partial protection, they do not 
prevent infection and have a limited effect on transmission. Therefore, there is a need for novel vaccines that confer 
a better protection. The present paper gives a short overview of the pathogenesis and immune responses follow-
ing M. hyopneumoniae infection, outlines the major limitations of the commercial vaccines and reviews the different 
experimental M. hyopneumoniae vaccines that have been developed and tested in mice and pigs. Most experimental 
subunit, DNA and vector vaccines are based on the P97 adhesin or other factors that are important for pathogen 
survival and pathogenesis. Other studies focused on bacterins combined with novel adjuvants. Very few efforts have 
been directed towards the development of attenuated vaccines, although such vaccines may have great potential. 
As cell-mediated and likely also humoral mucosal responses are important for protection, new vaccines should aim 
to target these arms of the immune response. The selection of proper antigens, administration route and type of 
adjuvant and carrier molecule is essential for success. Also practical aspects, such as cost of the vaccine, ease of pro-
duction, transport and administration, and possible combination with vaccines against other porcine pathogens, are 
important. Possible avenues for further research to develop better vaccines and to achieve a more sustainable control 
of M. hyopneumoniae infections are discussed.
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1 Introduction
Mycoplasma hyopneumoniae (M. hyopneumoniae) is the 
most important Mycoplasma sp. in swine health manage‑
ment. It is the primary pathogen of enzootic pneumonia, 
a chronic respiratory disease in pigs, and one of the pri‑
mary agents involved in the porcine respiratory disease 
complex [1]. Infections with M. hyopneumoniae are 
highly prevalent in almost all swine producing areas, and 
they cause significant economic losses due to increased 
medication use and decreased performance of the pigs 
[2].
Similar to other mycoplasmas, M. hyopneumoniae 
lacks a cell wall. The organism is very difficult to isolate 
because of its slow growth and potential overgrowth with 
other swine mycoplasmas. The pathogen‑host interac‑
tions are very complex and not fully characterized. The 
organism is primarily identified on the mucosal surface 
of the trachea, bronchi, and bronchioles [3]. It affects the 
mucosal clearance system by disrupting the cilia on the 
epithelial surface and, additionally, the organism modu‑
lates the immune system of the respiratory tract [4]. 
Therefore, M. hyopneumoniae predisposes animals to 
concurrent infections with other respiratory pathogens.
Control of M. hyopneumoniae infections in pig herds 
can be accomplished by optimizing management, hous‑
ing and biosecurity practices [5]. Treatment can be done 
using medication with antimicrobials active against M. 
hyopneumoniae. Antimicrobial medication can limit 
the consequences of the disease and decrease the infec‑
tion load [6], but it does not prevent pigs from becom‑
ing infected with M. hyopneumoniae. Medication with 
antimicrobials is also discouraged because of the risk of 
antimicrobial resistance development [7]. Vaccination 
against M. hyopneumoniae has been shown to be a useful 
tool to control M. hyopneumoniae infections. Different 
inactivated, whole‑cell vaccines are commercially avail‑
able and vaccination is frequently practiced worldwide. 
In infected herds, vaccination decreases clinical signs 
and lung lesions due to M. hyopneumoniae infections, 
performance losses of the animals and antimicrobial use. 
Although the commercial vaccines are widely used and 
cost‑efficient in many farms, they induce only a partial 
protection and do not prevent infection.
The present paper discusses the complex interaction 
of M. hyopneumoniae with the host and the limitations 
of the currently available commercial vaccines. Next, the 
different experimental vaccines that have been developed 
and tested in mice and pigs are reviewed. Finally, avenues 
for further research are provided in order to improve M. 
hyopneumoniae vaccination and achieve a more sustain‑
able control of M. hyopneumoniae infections.
2  Interactions of M. hyopneumoniae with the host
2.1  The organism
M. hyopneumoniae is a small (0.2–0.4  µm) and pleo‑
morphic organism as it lacks a shape‑defining cell‑wall. 
Studies have shown a high diversity at genomic, anti‑
genic, and proteomic level between different strains [8]. 
The genomes of the earliest described M. hyopneumo-
niae strains (the pathogenic strains 232 and 7448, and 
the nonpathogenic strain J) were sequenced in 2004 [9, 
10]. Since then, the genomes of several other strains 
have been sequenced. Currently, 23 entirely sequenced 
M. hyopneumoniae genomes are available, 11 already 
assembled and annotated, and 12 not fully assem‑
bled. In general, the genomes are small in size, namely 
0.86–0.96 Mb, and in each of them, there are 528 to 691 
protein‑encoding genes [11]. Despite the small genome, 
up to 30% of the gene content is still of unknown func‑
tion [12]. In addition, 20 to 30% of the M. hyopneumo-
niae genes encode surface proteins, the function of many 
of them is not yet known [12]. The mean GC content, 
which influences genome organization and gene expres‑
sion, is low (28.54%) compared to other bacterial species. 
The low GC content gives M. hyopneumoniae a complex 
transcriptional organization, unique intrinsic termina‑
tor stem‑loop formation and individual ribonuclease P 
(RNase P) structure [13].
The small genome of M. hyopneumoniae and the lim‑
ited number of secreted or surface proteins is particu‑
larly interesting for use of recombinant DNA technology. 
However, M. hyopneumoniae uses an unusual genetic 
code. The amino acid tryptophan is not encoded by 
TGG, but by TGA, which is a stop codon in most organ‑
isms [14]. This difference has hampered the expression 
of genes of M. hyopneumoniae containing TGA codons 
in E. coli, the most attractive system used for production 
of recombinant proteins. However, mutations replacing 
TGA codons with TGG have been used successfully to 
solve this problem [15].
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2.2  Adherence
Upon inhalation, M. hyopneumoniae adheres to the 
ciliated epithelial cells of the trachea, bronchi and 
bronchioles underneath the mucous layer. Adhesion is 
followed by the induction of ciliostasis, loss of cilia, and 
eventually epithelial cell death [16].
A repertoire of at least 35 M. hyopneumoniae proteins 
have been associated with cell adhesion, including sev‑
eral related to the P97/P102 paralog families and other 
surface proteins that moonlight as adhesins [17, 18]. 
The number of M. hyopneumoniae adhesins can even be 
higher, considering that its surfaceome includes more 
than 290 proteins and that many uncharacterized sur‑
face displayed proteins may bear adhesion properties. 
Different adhesins may vary in abundance at the cell 
surface between strains. This may be due to differential 
transcriptional rates of the respective genes, differential 
translational rates of the corresponding mRNAs and/or 
post‑translational events, including their export to the 
cell membrane and proteolytic processing. Proteolytic 
processing of adhesins can shape the bacterial surface 
architecture [19], generating several adhesin proteo‑
forms, that may exert alternative functions. Some of 
them are displayed at the cell surface, while others may 
stay in the cytoplasm or be released from the cell mem‑
brane to the extracellular milieu [11].
P97 is one of the most important adhesins of M. hyo-
pneumoniae and also the most intensively studied one, 
and therefore, it has been tested in many experimental 
vaccines. P97 contains two repeat regions (R1 and R2), 
located in the C‑terminal portion. The sites that are 
involved in cilium binding are located in the R1 region 
and at least seven AAKPV/E repeats are required for 
functional binding. Both R1 and R2 are involved in the 
attachment of M. hyopneumoniae to the extracellular 
matrix of the respiratory tract [20].
Apart from the cilia‑exposed glycans, some swine 
extracellular matrix molecules, such as fibronectin 
and plasminogen, also provide binding sites for surface 
adhesins of M. hyopneumoniae [11]. The fibronectin‑ 
and plasminogen‑binding ability of M. hyopneumoniae 
may mediate subsequent adherence to swine respira‑
tory cilia. Further research is needed to investigate 
whether adherence to fibronectin and plasminogen 
may facilitate internalization of M. hyopneumoniae 
and facilitate its traffic via the circulatory system and 
penetration into host organs, such as liver, kidneys and 
spleen [21]. The exact role of plasmin in the chronic 
inflammatory response as observed during M. hyo-
pneumoniae infection is unclear, but it may influence 
the migration of inflammatory cells and stimulate the 
release of pro‑inflammatory cytokines [22].
Extracellular actin is also used as a surface receptor by 
different proteoforms of M. hyopneumoniae P97 adhesin 
and other proteins, including lipoproteins, glycolytic 
enzymes, chaperones and translation factors [23]. Apart 
from extracellular actin, surface proteins of M. hyopneu-
moniae also interact with other cytoskeletal proteins, 
such as vimentin, keratin, tubulin, myosin, and tropomy‑
osin [24].
2.3  Virulence factors
Adhesion serves as the starting point of infection which 
is then assisted by other virulence factors. Classical 
virulence factors like toxins are generally lacking in 
Mycoplasma species. Mycoplasma hyopneumoniae can 
produce  H2O2 in the presence of glycerol in vitro. How‑
ever, this is strain dependent and the attenuated type 
strain J does not produce detectable amounts of  H2O2 
[25]. Whether production of hydrogen peroxide should 
be considered as a possible in vivo virulence mechanism 
in M. hyopneumoniae remains to be investigated. Fer‑
rarini et  al. [25] showed that M. hyopneumoniae is able 
to take up myo‑inositol and use it as an alternative energy 
source in the absence of glucose. Since myo‑inositol is 
freely available in the serum of pigs, it might be a suitable 
alternative energy source for M. hyopneumoniae residing 
in the highly vascularized lungs.
Lipid associated membrane proteins (LAMP) have 
also been implicated in the pathogenicity of mycoplas‑
mas. They interact with the host immune system mainly 
through Toll‑like receptors (TLRs), such as TLR2 [26]. In 
M. hyopneumoniae, whole membrane lipoprotein frac‑
tions induced apoptosis in various cell types, including 
porcine peripheral blood mononuclear cells (PBMCs) 
[27]. Furthermore, LAMPs activate production of nitric 
oxide and reactive oxygen species in the host cell [28].
Mycoplasmas need to scavenge nutrients including 
nucleotides from their environment and therefore, they 
are well known for their potent membrane nucleases [14]. 
A well‑recognized membrane nuclease is MnuA. Mac‑
rophages and neutrophils may form extracellular traps 
(METs or NETs, respectively), consisting of an interlace‑
ment of chromatin fibres rich in DNA, host defense pro‑
teins and enzymes, allowing immobilization and killing 
of invading microbes. In Mycoplasma bovis (M. bovis), 
MnuA was shown to degrade DNA‑based neutrophil 
and macrophage extracellular traps (NETs and METs, 
respectively), thereby enabling M. bovis to escape these 
traps [29] and not being killed by these innate immune 
cells. The nuclease‑encoding mnuA gene is also present 
in M. hyopneumoniae [30]. Therefore, MnuA could be a 
surface nuclease that is responsible for the degradation 
of NETs/METs, allowing M. hyopneumoniae to escape 
the host immune defense and using at the same time the 
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nucleotides and protein synthesis materials as nutrients 
for proliferation [31].
Mycoplasma hyopneumoniae may release extracellular 
DNA that allows the organism to form biofilms on abi‑
otic and host surfaces [32]. Biofilm formation makes the 
pathogen more resistant to antimicrobials and the host 
immune responses. The molecular interactions and cellu‑
lar processes underlying M. hyopneumoniae biofilm for‑
mation are thus far mostly unknown.
In Mycoplasma genitalium, an immunoglobulin (Ig) G 
binding protein, called protein M, has been identified. 
This protein not only fixes IgG very efficiently but also 
prevents subsequent antigen–antibody binding and sub‑
sequent signaling pathways of the bound antibodies [33]. 
In vitro experiments have shown that genes from Myco-
plasma mycoides subspecies capri encode a Mycoplasma 
Ig binding protein (MIB) and a Mycoplasma Ig protease 
(MIP). The complex of MIB and Ig is necessary for the 
proteolytic activity of MIP. The two proteins are encoded 
by two genes and are often detected in multiple copies in 
various Mycoplasma sp., including M. hyopneumoniae 
[34]. Further studies are needed to investigate the role of 
the MIB‑MIP system in virulence and immune evasion of 
M. hyopneumoniae.
Integrative and conjugative elements (ICE) are self‑
transmissible mobile genetic elements involved in hori‑
zontal gene transfer, thereby providing new virulence 
and/or antibiotic resistance traits. Such ICE have been 
identified in M. hyopneumoniae [35], but their role in 
encoding virulence traits of M. hyopneumoniae remains 
unclear.
Several large‑scale comparisons on the genome, tran‑
scriptome, proteome, metabolome and secretome level 
have been performed in order to investigate virulence 
and pathogenesis of M. hyopneumoniae [24, 36]. Liu et al. 
reported that besides the known virulence‑associated 
proteins (mainly adhesins), mutations were also found 
in genes involved in metabolism and growth [36]. M. 
hyopneumoniae is a genome‑reduced organism that is 
characterized by a limited set of biosynthetic pathways, 
as such it is not surprising that further loss of enzy‑
matic functions might have a large influence on survival 
and growth of the microorganism. This also holds true 
for lipoproteins involved in nutrient acquisition [37]. A 
comprehensive proteome profiling of two M. hyopneu-
moniae  strains and M. flocculare provided tens of novel 
candidates to enzootic pneumonia determinants or viru‑
lence factors [24].
2.4  Immune responses
The interaction of the pathogen with the immune system 
of the host is not yet fully elucidated, and it is clear that 
some components of the immune system may both help 
and hinder the development of Mycoplasma‑induced 
pneumonia [17, 38]. Infection induces the production of 
pro‑inflammatory (e.g. interleukin (IL)‑1β, IL‑6, TNF‑α) 
and immunoregulatory (e.g. IL‑10) cytokines by mac‑
rophages, neutrophils and lymphocytes in the lung. This 
excessive inflammatory response is associated with lym‑
phoid hyperplasia and is considered to be a major driver 
of lung lesions [39].
2.4.1  Innate immune responses
It has been shown that Toll‑like receptor 2 (TLR2) and 
TLR6 are important in the recognition of M. hyopneu-
moniae by porcine alveolar macrophages [40]. The acti‑
vation of this signal pathway leads to the production of 
pro‑inflammatory cytokines like TNF‑α, IL‑1β, and IL‑6 
by alveolar macrophages. Blocking TLR2 and TLR6 
receptors led to less TNF‑α production by macrophages 
[41], indicating that alveolar macrophages are involved 
in inflammatory and innate immune responses during 
M. hyopneumoniae infection. M. hyopneumoniae was 
also demonstrated to strongly activate monocytes and 
B cells in  vitro, with the B cell‑activation resulting in a 
potent polyreactive antibody response [42]. Neverthe‑
less, the role of these responses in protection against M. 
hyopneumoniae infection is still unknown. Also, it is not 
clear why there is a low neutrophil infiltration upon M. 
hyopneumoniae infection.
Recently, Mucha et al. [43] investigated changes in gene 
expression of swine epithelial cells of the trachea upon 
infection with M. hyopneumoniae. Among the up‑regu‑
lated genes, they found several genes related to immune 
response and inflammation, such as C3 complement, 
SAA3, chemokines (CXCL2 and CCL20) and galectins. 
These chemokines may attract myeloid cells. The study 
also suggested that ciliostasis caused by this pathogen 
might partially be explained by the down‑regulation of 
ciliary genes. The innate immune responses against M. 
hyopneumoniae and mycoplasma in general have been 
reviewed in more detail elsewhere [4].
2.4.2  Humoral responses
After experimental infection, M. hyopneumoniae‑specific 
serum IgG antibodies are detected 3–4 weeks post‑infec‑
tion (pi), peak after 11–12 weeks and then decrease very 
gradually [44]. After booster infection, serum antibody 
titers clearly increase and then slowly decline again [44]. 
Interestingly, pigs infected with a highly virulent strain 
appear to seroconvert earlier than pigs infected with a low 
virulent strain [45]. Mycoplasma hyopneumoniae‑specific 
IgM in serum can be detected as early as 9 days pi under 
experimental conditions. The percentage of IgM positive 
pigs peaks at 14 days pi and rapidly decreases afterwards 
[46]. When infection occurs naturally, seroconversion is 
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usually slower. Local M. hyopneumoniae‑specific anti‑
bodies precede specific serum antibodies following 
infection but decline faster [47]. Mycoplasma hyopneu-
moniae‑specific IgA can be detected in nasal swabs as 
early as 6 days pi, peak 12–16 days pi and decline steadily 
afterwards to reach pre‑immune levels by day 84 pi.
Mycoplasma hyopneumoniae‑specific IgG levels in 
serum induced by vaccination are not correlated with the 
severity of lung lesions in M. hyopneumoniae-infected 
pigs, suggesting that systemic antibodies play a minor 
role in protective immunity [48]. The role of mucosal 
antibodies in the protection against M. hyopneumoniae 
is still unclear. Some studies demonstrated that specific 
antibody levels in the respiratory tract did not correlate 
with protection [48, 49], whereas other studies empha‑
sized the role of M. hyopneumoniae‑specific secretory 
IgA in preventing adhesion of the microorganism to the 
ciliated cells of the respiratory tract [50–52]. Further‑
more, specific IgG diffusing from the blood into the lung 
tissue or produced locally in the BALT could opsonize 
M. hyopneumoniae, resulting in phagocytosis by mac‑
rophages and neutrophils [53]. However, Deeney et  al. 
[54] recently reported that addition of convalescent por‑
cine sera did not enhance engulfment of M. hyopneumo-
niae by alveolar macrophages in vitro.
2.4.3  Cell‑mediated responses
T cell‑mediated immune responses are generally con‑
sidered important for protection against Mycoplasmas 
causing local respiratory infections such as M. hyopneu-
moniae [4]. T cells are key in the regulation of immune 
responses and have a critical impact on the development 
of Mycoplasma‑induced pneumonia [38]. Mycoplasma 
pulmonis challenge studies using various T cell subset‑
depleted mice indicate that T helper 1 (Th1), Th17 and 
 CD8+ T cell responses are responsible for protection 
against Mycoplasma disease. In contrast, Th2 responses 
are less efficient in controlling the infection and thus con‑
tribute to immunopathology [38]. In a M. hyopneumo-
niae vaccination‑challenge study resulting in a significant 
reduction of lung lesions in the vaccinated group, Thacker 
et  al. [50] observed a higher level of IFN‑γ‑secreting 
blood lymphocytes in vaccinated pigs compared to non‑
vaccinated ones before and after experimental infection. 
In M. hyopneumoniae‑vaccination studies using a M. 
hyopneumoniae‑resistant and a non‑resistant pig line, 
higher serum levels of IFN‑γ and IL‑17A, but lower levels 
of IL‑4 and  CD4+ T cells were detected in the resistant 
line compared to the non‑resistant line after vaccination 
[55]. As IFN‑γ, IL‑4 and IL‑17A are the effector cytokines 
produced by Th1, Th2 and Th17 cells, respectively [4], 
these results support the findings obtained in mouse 
models that Th1 and Th17 responses are responsible for 
protection against Mycoplasma disease. Next to that, 
Marchioro et  al. [53] found a lower  CD4+/CD8+ ratio, 
and thus a higher relative number of  CD8+ cells in pigs 
vaccinated with a commercial M. hyopneumoniae bac‑
terin compared to control pigs receiving a physiological 
saline solution. This supports the hypothesis that  CD8+ 
T cells have a protective role in Mycoplasma infections 
and could partially explain the beneficial effects observed 
after vaccination against M. hyopneumoniae.
T helper 1 responses may contribute to protection 
against Mycoplasma infections by IFN‑γ‑mediated acti‑
vation of macrophage killing. It is now well‑established 
that Th17 immune responses are important to protect 
mucosal surfaces, to promote epithelial cell regenera‑
tion, mucous and antimicrobial protein production, and 
the release of neutrophil recruitment [56]. Following a 
mycoplasma infection, Th17 cells could protect the lung 
mucosa by attracting other immune cells for pathogen 
clearance [57] and by elevating secretory IgA levels in the 
airway lumen [58]. The major characteristic of  CD8+ cells 
is killing infected cells [59]. Since there is some evidence 
that M. hyopneumoniae is able to invade porcine epithe‑
lial cells [32], this characteristic of  CD8+ cells might be 
relevant in the immune response against M. hyopneumo-
niae. Interestingly, studies performed in the M. pulmonis 
mouse model suggest that  CD8+ T cells might dampen 
the pro‑inflammatory Th cell responses responsible for 
lung damage and clinical disease [38]. It is suggested that 
IFN‑γ‑producing  CD8+ T cells may skew the responses 
towards a protective Th1 response. Another possibility 
could be that  CD8+ T cells kill antigen presenting cells 
(APCs), thus reducing the possibility of Th cell activation 
[38].
3  Commercial vaccines against M. hyopneumoniae
3.1  Type of vaccines
Commercial vaccines mostly consist of adjuvanted inacti‑
vated, whole‑cell preparations (for an overview see Maes 
et al. [60]). Most vaccines are based on the strain J, possi‑
bly because it is the type strain of M. hyopneumoniae and 
grows easier in culture medium than recent field isolates. 
This strain was isolated in 1963 from a field outbreak of 
enzootic pneumonia in the UK. Commercial bacterin 
vaccines are licensed either for single or double vaccina‑
tion, and combinations with porcine circovirus type 2 
(PCV‑2) or Glaesserella parasuis (formerly Haemophilus 
parasuis) are available. Most bacterin vaccines should 
be administered intramuscularly, but some bacterins are 
also licensed for intradermal administration. An inacti‑
vated vaccine based on soluble antigens of M. hyopneu-
moniae is also commercially available [61].
Attenuated vaccines against M. hyopneumoniae have 
been licensed in Mexico and in China [62]. The vaccine 
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in Mexico is a thermosensitive mutant of M. hyopneumo-
niae (strain LKR) that should be applied intranasally [60]. 
The attenuated Chinese vaccine strain is derived from a 
virulent parent strain 168 isolated in 1974 from an Er‑
hua‑nian pig with enzootic pneumonia [63]. This field 
strain was gradually attenuated by continuous alternat‑
ing passage through modified Friis medium and pigs. The 
attenuated strain contains 60 insertions and 43 deletions 
compared to the original wild type strain. Mutations in 
genes related to metabolism and growth may contrib‑
ute to the attenuated virulence, in addition to variations 
previously described in M. hyopneumoniae adhesins 
(P97, P102, P146, P159, P216, and LppT), cell envelope 
proteins (P95), cell surface antigens (P36), and secreted 
proteins and chaperone protein (DnaK) [36]. The Chi‑
nese vaccine strain is mostly used by intrapulmonary 
administration [63]. Residual virulence and/or reversion 
to increased virulence might represent a risk in case of 
attenuated vaccines, although the Chinese vaccine has 
been used already for many years without reported side 
effects [60].
3.2  Mechanisms of protection upon vaccination
Commercial vaccines induce partial protection against 
M. hyopneumoniae infections. However, the immune 
mechanisms resulting in partial protection are not fully 
elucidated. Several studies observed lower levels of the 
pro‑inflammatory cytokines associated with lymphoid 
hyperplasia and pneumonia lesions, such as TNF‑α, Il‑6 
and IL‑1β in M. hyopneumoniae‑vaccinated pigs com‑
pared to non‑vaccinated ones [53, 64]. Moreover, vac‑
cinated pigs had a higher number of IL‑10‑producing 
cells in their bronchial lymph nodes, which may have 
an anti‑inflammatory effect [53]. Indeed, Vranckx et  al. 
[65] demonstrated that vaccination reduces macrophage 
infiltration in the BALT of experimentally infected pigs. 
These findings suggest that vaccination modulates the 
infiltration of immune cells, as well as the secretion of 
pro‑ and anti‑inflammatory cytokines, resulting in a 
reduction of lung lesions. Alternatively, it might also be 
possible that the reduced inflammatory responses is a 
consequence of a lower bacterial load [52].
The number of animals seroconverting after vaccina‑
tion, as well as the antibody levels induced in serum and 
respiratory tract washings may vary depending on the 
vaccine composition, administration route, vaccination 
strategy (single or double vaccination) and the infection 
status of the animal [60]. The serological response upon 
a single vaccination is generally lower than after dou‑
ble vaccination. Serum antibodies are usually detected 
from two to 4 weeks after two‑dose vaccination and they 
remain detectable for weeks to months. In the absence 
of natural infections that boost the immune system, 
antibody titers decrease below detection limits 1 to 
3  months after vaccination [66]. Early studies indicate 
no correlation between vaccine‑induced serum antibody 
levels and protection [67], but understanding the role of 
antibodies requires future investigations. Live‑attenuated 
vaccines applied via the mucosal route could theoreti‑
cally induce a local IgA response that could prevent col‑
onization but to our knowledge, such data has not been 
reported.
Several studies found an increase in M. hyopneumo-
niae‑specific IFN‑γ‑secreting cells in the blood and lung 
tissue of vaccinated animals [53, 64, 68]. These cells, 
characteristic for local and systemic Th1 responses, are 
considered to play an important role in vaccine‑induced 
protection.
3.3  Efficacy of commercial vaccines
The major advantages of piglet vaccination relate to 
increased animal welfare and a decrease of the per‑
formance losses due to M. hyopneumoniae infections: 
improvement of daily weight gain (2–8%), feed conver‑
sion ratio (2–5%) and sometimes mortality rate. Addi‑
tionally, shorter time to reach slaughter weight, less 
variation in slaughter weight (more homogeneous car‑
casses), reduced clinical signs (coughing), lower preva‑
lence and severity of lesions typically caused by M. 
hyopneumoniae and lower treatment costs, are observed 
[69]. The currently used vaccines reduce the number of 
M. hyopneumoniae organisms in the respiratory tract [52, 
65, 70] and decrease the infection level in a herd [71].
Different factors that may influence vaccine efficacy 
have been described by Maes et al. [60]. The most impor‑
tant factors include non‑compliance with the basic prin‑
ciples of good vaccination practices, stress at vaccination, 
infections with other pathogens at the moment of vac‑
cination, important co‑infections involved in porcine 
respiratory disease complex, diversity of M. hyopneumo-
niae strains, and maternal immunity. A recent study [72] 
also hinted at a role of pre‑vaccination gut microbiota 
composition in influencing M. hyopneumoniae vaccine 
responses, although bacterial diversity indexes alone 
were not predictive for antibody responses among indi‑
vidual pigs.
Drawbacks of the current vaccines are that the pro‑
tection against clinical signs and lesions typically 
caused by M. hyopneumoniae is often incomplete and 
vaccination does not prevent colonization. Transmis‑
sion models under experimental [70] and field condi‑
tions [45, 73] also showed that vaccination conferred 
only a limited and non‑significant reduction of the 
transmission rate of M. hyopneumoniae. New vaccines 
and/or administration routes are therefore needed. A 
recent pilot study could not demonstrate transmission 
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of M. hyopneumoniae between seeder and contact ani‑
mals in case both had been vaccinated multiple times 
against M. hyopneumoniae [74], suggesting that also 
the effect of vaccination frequency should be further 
explored.
4  Experimental vaccines
Research on the development of novel vaccines that 
may offer better protection against M. hyopneumo-
niae infections is ongoing. An overview of the peer‑
reviewed studies (since 1995) that have investigated 
different experimental vaccines in mice is shown in 
Table  1 (vector vaccines), Table  2 (subunit vaccines) 
and Table  3 (DNA vaccines), while studies that were 
conducted in pigs are shown in Table  4 (vector vac‑
cines), Table  5 (subunit, membrane proteins, culture 
supernate vaccines) and Table  6 (bacterin vaccines). 
Peer‑reviewed studies about nucleic acid‑based vac‑
cines against M. hyopneumoniae in pigs were not 
found. No publications in peer‑reviewed scientific 
journals have been found about experimental vaccines 
based on attenuated strains.
4.1  Experimental vaccines studied in mice
The studies in mice focused on the construction and 
development of the vaccines and the evaluation of the 
immune responses. As M. hyopneumoniae is only causing 
disease in pigs, the efficacy of the vaccines was not tested 
in mice. All studies assessed the humoral responses in 
serum, many also included cell‑mediated immunity 
(CMI), whereas the humoral response in the BAL fluid 
was less frequently examined.
In terms of antigen selection, most studies included 
outer membrane proteins that are immunogenic and/
or considered important for adhesion such as P97, P46, 
P71 and P95. However, also other antigens were tested 
such as NrdF, P36, HSP70, P42, P37 and MnuA. NrdF is 
an essential enzyme for metabolic processes. It catalyzes 
the conversion of ribonucleoside diphosphates to deoxy‑
ribonucleoside diphosphates, an essential step in DNA 
replication [75]. P36 or L‑lactate dehydrogenase is an 
early immunogenic protein [79]. HSP70 is a 70 kDA heat 
shock protein that has been used successfully as a vaccine 
antigen for other pathogens such as Salmonella Typhi in 
mice and Mycobacterium avium subsp. paratuberculo-
sis in cattle [85]. P42 is also a heat shock protein and is a 
Table 1 Experimental vector vaccines against Mycoplasma hyopneumoniae tested in mice. 
IM, Intramuscular; IN, Intranasal.
a CMI cell-mediated immune responses were tested by stimulation of splenocytes.
b BALF bronchoalveolar lavage fluid.
Antigen Vector Route Nb of 
vaccinations




NrdF (R2) Salmonella Typh-
imurium aroA 
SL3261
Oral 3 No IgG, no IgA IgA, no IgG [75]
P97 (R1) Salmonella Typh-
imurium aroA 
CS332 (pro- and 
eukaryotic 
plasmid)
Oral 2 No No IFN-γ [76]
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member of the HSP70 family [86]. It is highly expressed 
under stress conditions, and specific antibodies against 
P42 were able to block the growth of M. hyopneumoniae. 
P37 is a lipoprotein that belongs to the ATP‑binding cas‑
sette (ABC) transporters [90], whereas MnuA is a mem‑
brane nuclease and considered a potential virulence 
factor [91]. The antigens in the vaccines were produced 
by recombinant DNA technology using E. coli as expres‑
sion system.
Most vector vaccines were based on bacterial vectors 
namely Salmonella, Actinobacillus and Bacillus, while 
two studies used adenovirus vectors. The subunit vac‑
cines were based on single antigens or different anti‑
gens that were mixed with an adjuvant. In three of the 
five studies, the antigens were constructed as a chimeric 
protein. Subunit vaccines were used in combination with 
adjuvants based on oil, aluminium hydroxide, the B sub‑
unit of heat‑labile enterotoxin of E. coli (LTB) or Myco-
bacterium tuberculosis ESAT‑6 protein. Vaccination with 
DNA constructs encoding potential antigens might be 
promising, as in general, DNA constructs are stable, easy 
to handle and can be administered via various routes.
Most vaccines in mice were applied two or three 
times, and were administered via the parenteral route, 
mainly intramuscularly, although oral (vector vaccines), 
intranasal and intraperitoneal administration routes 
were evaluated as well.
The major outcome parameters of the studies in mice 
were humoral responses in serum and in some stud‑
ies also in BAL fluid, and CMI responses. Humoral 
responses in serum were assessed by measuring IgG 
against the antigens included in the vaccine, some stud‑
ies also measured isotypes of IgG. In general, IgG1 in 
mice is indicative of a Th2 response, whereas IgG2a is 
predominantly produced during a Th1‑type response 
[92]. CMI responses were examined by isolation and 
subsequent stimulation of splenocytes with the respec‑
tive antigens. IFN‑γ production by splenocytes was 
measured in every study, other cytokines (IL‑10, IL‑4, 
TNF‑α) were less frequently assessed.
The immune responses with the orally applied Sal-
monella vector vaccine were poor, IgA was only found 
in BAL fluid in one study and IFN‑γ production in 
another study (Table  1). The immune responses with 
the other vector vaccines that were administered intra‑
muscularly or intranasally were more pronounced, 
but also variable between studies. When used under 
field conditions, vector vaccines might have the prob‑
lem that immunity is present in the animals against 
Table 3 Experimental DNA vaccines against Mycoplasma hyopneumoniae tested in mice. 
IM, Intramuscular; SC, Subcutaneous; IP, intraperitoneal.
a CMI responses were tested by stimulation of splenocytes.
Antigen Vaccine type Vector/
adjuvant
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the vector micro‑organism e.g. Salmonella, leading to 
lower expression of and immunity against the carried 
antigen.
The immune responses following administration of 
subunit vaccines (Table 2) were more consistently meas‑
ured compared to those of the vector vaccines. Mostly, 
mixed Th1/Th2 responses were obtained. Immune 
responses were generally more pronounced when differ‑
ent antigens were presented in a chimeric form [83, 84, 
86]. Possibly, in these studies, the epitopes were better 
accessible by the immune system in the chimeric pro‑
teins. Immunization by the intramuscular route appeared 
to favor a Th1‑type response (higher IgG2/IgG1 ratio), 
while the intranasal route induced a mixed response [78, 
83]. Adding Mycobacterium tuberculosis ESAT‑6 pro‑
tein or the gene sequences as adjuvant also shifted the 
immune response towards a Th1‑type response [82].
Vaccination with the DNA constructs elicited mixed 
responses (Table  3), with predominance for Th1‑type 
responses [87, 91]. IgA in BAL fluid was not tested. Th1‑
type responses stimulate B‑cells to produce strongly 
opsonizing antibodies, such as IgG2a and IgG2b in mice, 
enhancing the phagocytosis by alveolar macrophages. 
In mice, IFN‑γ, produced by Th1‑type cells, induces 
nitric oxide release from monocytes/macrophages. In 
case genes coding for multiple antigens were included 
[89–91], the responses were variable between the anti‑
gens, and could also be different when compared to 
the response obtained by the respective single subunit 
vaccines.
Overall, some studies showed promising immune 
responses in mice. However, many phenotypic as well as 
functional differences in immune cell populations exist 
between the porcine and the murine immune system 
[93]. Therefore, studies in mice should be considered as 
preliminary and need to be validated in pigs.
4.2  Experimental vaccines studied in pigs
The experimental vaccine studies in pigs are summarized 
in Tables 4, 5 and 6. Most of the studies in pigs used an 
experimental challenge infection model, allowing to 
assess the efficacy of the vaccines. CMI responses in pigs 
were tested by stimulation of PBMCs and subsequently 
measuring the stimulation index (vector vaccines) or 
specific cytokine responses (bacterin vaccines). No CMI 
responses were measured in the studies with the subunit 
vaccines.
The antigen selection for the vector and subunit vac‑
cines mostly included the P97, alone or in combination 
with other antigens e.g. NrdF, P42 or P102. One study 
used membrane proteins [48] and two studies used 
cell‑free culture supernatant of M. hyopneumoniae [99, 
100]. The bacterin vaccines were based on the strains 
PRIT‑5 [103, 104] and F7.2C [105, 106]. Subunit and 
bacterin vaccines were mostly used in combination 
with an adjuvant such as aluminium hydroxide, Fre‑
und’s adjuvant (both complete or incomplete), bacterial 
toxin subunits (LTB), oil or polymer‑based adjuvants, 
macrophage‑inducible C‑type lectin (MINCLE) ago‑
nist, the stimulator of interferon genes (STING) ligand 
and a combination of different TLR ligands. Vectors 
used were Salmonella Typhimurium, Erysipelothrix 
rhusiopathiae and adenovirus. Vector vaccines were 
administered orally or intranasally, while most subu‑
nit and bacterin vaccines were administered parenter‑
ally. In two studies, the bacterin was provided orally in 
microspheres [103, 104]. All experimental vaccines in 
pigs were applied two or three times.
In terms of efficacy, 11 out of 14 studies showed a sig‑
nificant reduction of the lung lesions caused by M. hyo-
pneumoniae upon challenge infection. Two out of five 
studies showed a reduction of clinical signs (coughing), 
and five out of eight a reduction of the M. hyopneumo-
niae load in the BAL fluid. Three studies [21, 52, 97] 
included a commercial bacterin as control. Their effi‑
cacy was each time better than for the experimental 
vaccines, although the immune responses against the 
epitopes of the experimental vaccines were lower or 
absent upon vaccination with the commercial vaccines. 
This might be due to the fact that some proteins of the 
bacterins might not be expressed or only expressed in 
negligible amounts under culture conditions [107], or 
to the formulation or the adjuvant. Proteomic analy‑
sis by Pendarvis et  al. [108] showed that only 483 of 
691 (70%) proteins in M. hyopneumoniae 232 strain 
were expressed under in  vitro culture conditions. This 
might be one of the reasons of the incomplete protec‑
tion induced by commercial vaccines. Nonetheless, the 
efficacy of the experimental vaccines was even lower, 
suggesting that immunity induced by the antigens 
selected for preparing these vaccines is not sufficient 
for improved protection, although it is well known 
that these antigens like P97 have important roles in the 
pathogenesis of M. hyopneumoniae infections.
All studies could demonstrate specific IgG responses 
in the serum, except for two vector vaccines [94, 95]. In 
all studies that had measured mucosal IgA responses 
in the BAL fluid, IgA could only be detected after chal‑
lenge infection, but not after vaccination prior to chal‑
lenge (four studies used intramuscular, two studies oral 
administration). In three studies [97, 103, 104], IgA was 
detected in the saliva and/or nose after vaccination and 
prior to challenge infection. In these studies, pigs were 
vaccinated intranasally, orally or intramuscularly. In the 
pigs vaccinated intramuscularly, IgA levels in the saliva 
and especially in the nose were low [103, 104].
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In terms of CMI responses, all studies with the vector 
vaccines could demonstrate significant responses upon 
specific stimulation of PBMCs. None of the studies with 
subunit vaccines (Table  5) describe assessment of CMI 
responses. For the bacterin vaccines, CMI responses 
were only assessed in the studies of Matthijs et al. [105, 
106]. The study of Matthijs et  al. [105] did not apply 
challenge infection, but made a detailed assessment of 
the immune responses of five different bacterin formu‑
lations. They were all based on a more recently isolated 
field strain of M. hyopneumoniae compared to the type 
strain J, in combination with different novel adjuvants. 
These included different Toll‑like receptor ligands (tar‑
geting TLR1/2, TLR7/8, TLR9), the MINCLE agonist 
trehalose 6,6‑dibehenate (TDB), and STING ligand 
cyclic diadenylate monophosphate (c‑di‑AMP). They 
were used in combination with different carriers namely 
liposomes, polylactic‑co‑glycolic acid (PLGA) micropar‑
ticles or squalene‑in‑water emulsion (SWE) (see Table 6). 
The responses were variable depending on the group. 
Lipo_DDA:TDB, Lipo_AMP and SWE_TLR significantly 
induced Th1 cytokine‑secreting T cells. Only PLGA_TLR 
appeared to induce Th17 cells, but was unable to induce 
serum antibodies.
The study of Matthijs et al. [106] also applied a systems 
vaccinology approach developed for humans and adapted 
the approach for use in pigs. The transcriptomic analy‑
ses demonstrated that the induction of inflammatory and 
myeloid cell blood transcriptional modules (BTM) in the 
first 24  h after vaccination correlated well with serum 
antibodies, while negative correlations with the same 
modules were found seven days post vaccination. Fur‑
thermore, many cell cycle and T cell BTM upregulated 
at day seven, correlated positively with adaptive immune 
responses. When comparing the delivery of the identi‑
cal TLR ligands with the three formulations, SWE_TLR 
was shown to be more potent in the induction of an 
early innate immune response, while the liposomal for‑
mulation more strongly promoted late cell cycle and T 
cell BTM. For the PLGA formulation, there were signs 
of a delayed and weak perturbation of these BTM. The 
study of Matthijs et al. [105] demonstrated the utility of 
transcriptome‑based systems immunology analyses in 
identifying early immune signatures in the blood and in 
unraveling the mechanistic events leading to the stimu‑
lation of adaptive immune responses after vaccine injec‑
tion in pigs.
In a subsequent study, Matthijs et  al. [106] assessed 
the efficacy of three bacterin formulations that were 
able to induce a Th1 or Th17 response in the previous 
study, namely a cationic liposome formulation with the 
Mincle receptor ligand trehalose 6,6‑dibehenate (Lipo_
DDA:TDB), a squalene‑in‑water emulsion with Toll‑like 
receptor (TLR) ligands targeting TLR1/2, TLR7/8 and 
TLR9 (SWE_TLR), and a poly(lactic‑co‑glycolic acid) 
microparticle formulation with the same TLR ligands 
(PLGA_TLR). All three formulations showed promising 
results, but the highest CMI responses were obtained 
in the SWE_TLR group. This experimental vaccine also 
showed the best efficacy in terms of reducing clinical 
signs, lung lesions and bacterial load in the lung.
Overall, the research with the different experimental 
vaccines in pigs suggests that the construction, the type 
of antigens, the adjuvant and/or carrier, and the route 
and frequency of immunization could induce variable 
immune responses and efficacy. Based on the available 
studies, it is not possible to unravel the effect of one of 
these characteristics e.g. antigen, adjuvant and admin‑
istration route, as the studies were not designed for this 
purpose and differ each time in more than one charac‑
teristic. In addition, the studies listed in Tables  1 and 
2 also point to a large variation in individual animal 
responses, even if the same vaccine is used under the 
same conditions.
5  Avenues for further research
As far as this was investigated, the experimental vaccines 
that have been tested in pigs (Tables 4, 5, 6) do not pro‑
vide superior protection compared to the commercially 
available bacterin vaccines. Therefore, further research 
on the development of new experimental vaccines and 
validation of the efficacy of promising vaccines in pigs is 
needed.
From an immunological point of view, a major chal‑
lenge is to induce a protective immunity at the mucosal 
surface of primary adherence and multiplication of M. 
hyopneumoniae, namely the ciliated epithelium of the 
trachea, bronchi and bronchioli. From a practical view‑
point, also aspects such as cost of the vaccine, ease of 
production, transport and administration, differentiation 
of infected from vaccinated animals (DIVA), and possible 
combination with other vaccines are important.
5.1  Administration route
Administration of the antigens intranasally or via aero‑
sols might be the most appropriate routes to accomplish 
mucosal protection. The number of experimental vac‑
cines that have evaluated this route of immunization is 
still very limited. This is mainly due to important diffi‑
culties that are encountered by using the mucosal route 
such as: (1) the antigen should be present at and below 
the mucosal barrier in sufficient amounts allowing suf‑
ficient capturing by antigen presenting cells, (2) mucosal 
tolerance mechanisms should be overcome, (3) protec‑
tive immune mechanisms should be activated and, (4) 
minimal/or no influence on mucosal functionality should 
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occur. Mucosal adjuvants e.g. microbe‑derived sub‑
stances, including TLR ligands, could be crucial in reach‑
ing these goals [109, 110]. Heterologous prime‑boost 
regimes e.g. intramuscular followed by mucosal adminis‑
tration or vice versa, allowing a broader or more variable 
triggering of the immune system, might also be consid‑
ered. Vaccination via aerosols is probably technically pos‑
sible, as nebulization of lung homogenate positive for M. 
hyopneumoniae to gilts under field conditions, resulted 
in infection of the animals with this pathogen [111]. Also, 
Feng et al. [62] showed that the attenuated vaccine used 
in China could be administrated as an aerosol.
Providing the antigen orally might also induce mucosal 
immunity in the respiratory tract via the common 
mucosal immune system [112]. In the studies of Lin et al. 
[103, 104], microencapsulated inactivated whole‑cell M. 
hyopneumoniae vaccine was administered orally to pigs 
via a tube into the esophagus on three occasions. IgA was 
detected in nasal secretions and saliva, but IgA was not 
measured in BAL fluid. However, lung lesions following 
challenge infection were significantly reduced in vacci‑
nated pigs, pointing to protective immunity in these ani‑
mals. Placing a tube in the esophagus is labor intensive, 
time consuming and not animal welfare friendly. The 
stability of the antigen during the mouth‑stomach‑intes‑
tine passage might also be an issue. Therefore, further 
research should focus on whether M. hyopneumoniae 
vaccines mixed in the diet and consumed by the pigs can 
also provide protection. Such a method might require a 
higher antigen dose and also the stability of the antigen 
in the feed might be an issue. However, it would be ani‑
mal welfare friendly and require much less time and labor 
than administration of the vaccine via a tube to each indi‑
vidual animal.
Most experimental vaccines were applied via the par‑
enteral route, mostly intramuscularly. The studies using 
parenteral administration however could not demon‑
strate measurable IgA responses in the BAL fluid prior 
to challenge, and therefore, this route is less suitable for 
inducing mucosal humoral responses. However, higher 
M. hyopneumoniae‑specific IgA levels were observed in 
respiratory tract washings of parenterally vaccinated pigs 
compared to non‑vaccinated pigs after challenge infec‑
tion, indicating an anamnestic immune response. This 
suggests that priming of the mucosal immune system is 
possible after parenteral vaccine administration. Intra‑
dermal vaccination directly targets epidermal Langer‑
hans cells and dermal dendritic cells, which are essential 
for efficient T and B cell priming. In this sense, intra‑
dermal vaccination against M. hyopneumoniae can be 
an asset, as more of these specialized APCs are present 
in the skin compared to muscle tissue [113]. In addi‑
tion, no needles are used as the vaccine is administered 
intradermal via pressure, which may reduce the risk for 
iatrogenic infections.
5.2  Antigen
Bacterial genes and antigens involved in survival of the 
bacterium in the host and/or that render the bacte‑
rium harmful to the host could be included in vaccines 
or could be targets for attenuation to develop attenu‑
ated vaccines. Many experimental vaccine studies have 
included P97 and other proteins that are important for 
adherence or metabolism. However, subunit vaccines 
based on the most important adhesion namely P97, did 
not provide sufficient protection. The adhesion process 
is complex and involves many different adhesins, there‑
fore, including one or only a few antigens might be insuf‑
ficient. This might also explain why bacterins, which 
include a broad array of antigens, perform better in terms 
of efficacy than subunit vaccines. Further research on 
subunit vaccines should therefore not focus on one or a 
few antigens, but include different and carefully selected 
antigens.
5.3  Adjuvant and carrier
Adjuvants are incorporated into vaccines to increase and 
direct the immunogenic responses to antigens. Many 
adjuvants activate the innate immune system through 
pattern‑recognition receptors (PRRs) present in immune 
cells. Receptor‑ligand interactions lead to expression of 
genes that encode cytokines, chemokines, and costimu‑
latory molecules responsible for priming, expansion, and 
polarization of immune responses [114]. Adjuvants can 
also induce adaptive immune responses either by enhanc‑
ing T cell responses, by stimulating humoral immunity or 
both. As Th1 and Th17 responses are considered impor‑
tant for protection against M. hyopneumoniae infection, 
adjuvants that stimulate this arm of the immune system 
should preferably be selected [105]. Commonly used 
adjuvants and their modes of action along with strengths 
and weaknesses have been reviewed by Bastola et  al. 
[114].
Adjuvants not only increase the immunogenic 
responses, but can also lead to adverse reactions such as 
inflammation at the injection site, granuloma and ster‑
ile abscess formation, malaise, fever and other systemic 
reactions. Apart from the study of Matthijs et  al. [105], 
information about safety of adjuvants in experimental 
M. hyopneumoniae vaccines is very scarce. Research on 
adjuvant development should therefore not only identify 
more inflammatory adjuvants, but also try to separate the 
potency of adjuvants from the adverse effects they can 
induce.
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5.4  Attenuated vaccines
Attenuated vaccines have great potential to better stimu‑
late a mucosal immune response at the respiratory tract 
compared to parenterally administered vaccines. How‑
ever, apart from the two current commercially available 
attenuated M. hyopneumoniae vaccines, very few studies 
have focused on developing experimental attenuated M. 
hyopneumoniae vaccines. This might be due to the dif‑
ficult isolation and cultivation characteristics of M. hyo-
pneumoniae. In addition, reversion of virulence is always 
a concern in case of attenuated vaccines. One study [115] 
tested whether a low virulent M. hyopneumoniae strain 
could be used as a potential vaccine. However, infection 
with this strain did not protect piglets against infection 
with a highly virulent M. hyopneumoniae isolate 1 month 
later, suggesting that low virulent strains might not be 
suitable as such to be used as vaccines. Current technol‑
ogy allows however to selectively delete specific genes 
important for replication or virulence in pathogenic 
organisms, which might be useful for the development of 
attenuated vaccines against M. hyopneumoniae. At this 
stage however, these genes are not yet fully elucidated, 
and therefore, further research is needed to investigate 
genes of M. hyopneumoniae involved in pathogenesis and 
virulence.
6  Conclusions
The very complex interaction of M. hyopneumoniae with 
the respiratory tract and the immune system and the fact 
that naturally elicited immune responses upon infection 
are not able to rapidly clear the pathogen from the ani‑
mal, make the search for protective immune responses 
and efficacious novel vaccines challenging. Different 
experimental vaccines against M. hyopneumoniae have 
been developed and tested in mice and pigs. Most of 
them were based on the P97 adhesin or other factors con‑
sidered important in the pathogenesis, or were bacterins 
combined with novel adjuvants. As cell‑mediated and 
likely also mucosal humoral responses are important for 
protection, new vaccines should aim to target these arms 
of the immune response. Very few research has been 
directed towards the development of attenuated vac‑
cines, although such vaccines may have great potential.
Abbreviations
ABC: ATP-binding cassette; APC: Antigen presenting cell; BAL: Bronchoalveolar 
lavage; BTM: Blood transcriptional modules; c-di-AMP: Cyclic di-adenylate 
monophosphate; CMI: Cell-mediated immunity; DC: Dendritic cell; DDA:TDB: 
Dimethyl dioctadecylammonium:trehalose 6,6-dibehenate; DIVA: Differen-
tiation of infected from vaccinated animals; HSP: Heat shock protein; ICE: 
Integrative and conjugative elements; IFN: Interferon; Ig: Immunoglobulin; 
IL: Interleukin; IN: Intranasal; LAMP: Lipid associated membrane proteins; LTB: 
Heat-labile enterotoxin of E. coli; M. hyopneumoniae: Mycoplasma hyopneumo-
niae; MET: Macrophage extracellular trap; MIB: Mycoplasma Ig binding protein; 
MINCLE: Macrophage-inducible C-type lectin; MIP: Mycoplasma Ig protease; 
NET: Neutrophil extracellular trap; NK: Natural killer; NrdF: Ribonucleoside-
diphosphate reductase; PBMC: Peripheral blood mononuclear cell; PGLA: 
Poly(lactic-co-glycolic acid); STING: Stimulator of interferon genes; SWE: 
Squalene-in-water; Th: T helper; TLR: Toll-like receptor; TNF: Tumor necrosis 
factor.
Authors’ contributions
DM wrote the paper. All co-authors have critically revised the manuscript, 
FB, PK and FH with emphasis on the bacteriological aspects, BV and AS with 
emphasis on the immune responses and vaccination. The authors have col-
laborated intensively on the topic during the H2020 Project SAPHIR (Project 




The authors declare that they have no competing interests.
Author details
1 Faculty of Veterinary Medicine, Ghent University, Merelbeke, Belgium. 
2 Institute of Veterinary Bacteriology, Vetsuisse Faculty, University of Bern, Bern, 
Switzerland. 3 Institute of Virology and Immunology, Sensemattstrasse 293, 
Mittelhäusern, Switzerland. 4 Department of Infectious Diseases and Pathobiol-
ogy, Vetsuisse Faculty, University of Bern, Bern, Switzerland. 
Received: 17 February 2021   Accepted: 23 April 2021
References
 1. Pieters M, Maes D (2019) Mycoplasmosis. In: Zimmermann JJ, Karriker 
LA, Ramirez A, Schwartz KJ, Stevenson GW, Zhang J Diseases of swine 
(11 ed). Hoboken, NJ, Wiley. pp: 863–883
 2. Marois C, Segalés J, Holtkamp D, Chae C, Deblanc C, Opriessnig T, Fablet 
C (2020) Interactions of Mycoplasma hyopneumoniae with other patho-
gens and economic impact. In: Book Mycoplasmas in Swine. Chapter 7. 
Editors: Dominiek Maes, Marina Sibila, Maria Pieters. ISBN 978-94-6379-
796-2, Acco Publishers, Leuven Belgium, 127–145
 3. Blanchard B, Vena MM, Cavalier A, Le Lannic J, Gouranton J, Kobisch 
M (1992) Electron microscopic observation of the respiratory tract of 
SPF piglets inoculated with Mycoplasma hyopneumoniae. Vet Microbiol 
30:329–341
 4. Summerfield A (2020) Immune responses against porcine Mycoplasma 
infections. In: Book Mycoplasmas in Swine. Chapter 6. Editors: Dominiek 
Maes, Marina Sibila, Maria Pieters. ISBN 978-94-6379-796-2, Acco Pub-
lishers, Leuven Belgium, pp. 110–125
 5. Marco E, Yeske P, Pieters M (2020) General control measures against 
Mycoplasma hyopneumoniae infections. In: Book Mycoplasmas in 
Swine. Chapter 9. Editors: Dominiek Maes, Marina Sibila, Maria Pieters. 
ISBN 978-94-6379-796-2, Acco Publishers, Leuven Belgium. pp. 163–180
 6. Thacker E, Thacker B, Wolff T (2004) Efficacy of a chlortetracycline feed 
additive in reducing pneumonia and clinical signs induced by experi-
mental Mycoplasma hyopneumoniae challenge. J Swine Health Prod 
14:140–144
 7. Collignon PJ, McEwen SA (2019) One health-its importance in helping 
to better control antimicrobial resistance. Trop Med Infect Dis 4:22
 8. Jarocki V, Djordjevic S (2020) Diversity of Mycoplasma hyopneumoniae 
strains. In: Book Mycoplasmas in Swine. Chapter 2. Editors: Maes D, 
Sibila M, Pieters M. ISBN 978-94-6379-796-2, Acco Publishers, Leuven 
Belgium. pp. 47–71
 9. Minion FC, Lefkowitz E, Madsen M, Cleary B, Swartzell S, Mahairas G 
(2004) The genome sequence of Mycoplasma hyopneumoniae strain 
232, the agent of swine mycoplasmosis. J Bacteriol 186:7123–7133
 10. Vasconcelos A, Ferreira H, Bizarro C, Bonatto S, Carvalho M, Pinto P, 
Almeida DF, Almeida LGP, Almeida R, Alves-Filho L, Assunção EN, 
Azevedo VAC, Bogo MR, Brigido MM, Brocchi M, Burity HE, Camargo AA, 
Camargo SS, Carepo MS, Carraro DM, de Mattos Cascardo JC, Castro LA, 
Cavalcanti G, Chemale G, Collevatti RG, Cunha CW, Dallagiovanna B, 
Page 18 of 20Maes et al. Vet Res           (2021) 52:67 
Dambrós BP, Dellagostin OA et al (2005) Swine and poultry patho-
gens: the complete genome sequences of two strains of Mycoplasma 
hyopneumoniae and a strain of Mycoplasma synoviae. J Bacteriol 
187:5568–5577
 11. Leal Zimmer F, Paes J, Zaha A, Ferreira H (2020) Pathogenicity & viru-
lence of Mycoplasma hyopneumoniae. Virulence 11:1600–1622
 12. Felde O, Kreizinger Z, Sulyok KM, Hrivnák V, Kiss K, Jerzsele A, Biksi I, 
Gyuranecz M (2018) Antibiotic susceptibility testing of Mycoplasma 
hyopneumoniae field isolates from Central Europe for fifteen antibiotics 
by microbroth dilution method. PLoS One 13:e0209030
 13. Fritsch TE, Siqueira FM, Schrank IS (2015) Intrinsic terminators in Myco-
plasma hyopneumoniae transcription. BMC Genomics 16:273–284
 14. Rycroft A (2020) Overview of the general characteristics and classifica-
tion of porcine Mycoplasma species. In: Book Mycoplasmas in Swine. 
Chapter 1. Editors: Maes D, Sibila M, Pieters M. ISBN 978-94-6379-796-2, 
Acco Publishers, Leuven Belgium. pp. 25–46
 15. Simionatto S, Marchioro SB, Galli V, Luerce T, Hartwig D, Moreira A, Del-
lagostin O (2009) Efficient site-directed mutagenesis using an overlap 
extension-PCR method for expressing Mycoplasma hyopneumoniae 
genes in Escherichia coli. J Microbiol Methods 79:101–105
 16. Debey MC, Ross RF (1994) Ciliostasis and loss of cilia induced by 
Mycoplasma hyopneumoniae in porcine tracheal organ cultures. Infect 
Immun 62:5312–5318
 17. Maes D, Sibila M, Kuhnert P, Segalés J, Haesebrouck F, Pieters M (2018) 
Update on Mycoplasma hyopneumoniae infections in pigs: knowledge 
gaps for improved disease control. Transbound Emerg Dis 65:110–124
 18. Kuhnert P, Jores J (2020) Mycoplasma hyopneumoniae pathogenicity: 
the know and the unknown. In: Book Mycoplasmas in Swine. Chapter 3. 
Editors: Maes D, Sibila M, Pieters M. ISBN 978-94-6379-796-2, Acco 
Publishers, Leuven Belgium. pp. 71–84
 19. Raymond BB, Jenkins C, Seymour LM, Tacchi J, Widjaja M, Jarocki V, 
Deutscher A, Turnbull L, Whitchurch C, Padula M, Djordjevic S (2015) 
Proteolytic processing of the cilium adhesion MHJ_0194 (P123J) in 
Mycoplasma hyopneumoniae generates a functionally diverse array of 
cleavage fragments that bind multiple host molecules. Cell Microbiol 
17:425–444
 20. Jenkins C, Wilton JL, Minion FC, Falconer L, Walker MJ, Djordjevic SP 
(2006) Two domains within the Mycoplasma hyopneumoniae cilium 
adhesin bind heparin. Infect Immun 74:481–487
 21. Marchioro S, Del Pozo SR, Michiels A, Haesebrouck F, Conceição F, 
Dellagostin O, Maes D (2014) Immune responses of a chimeric protein 
vaccine containing Mycoplasma hyopneumoniae antigens and LTB 
against experimental M. hyopneumoniae infection in pigs. Vaccine 
32:4689–4694
 22. Kucharewicz I, Kowal K, Buczko W, Bodzenta-Lukaszyk A (2003) The 
plasmin systemin airway remodelling. Thromb Res 112:1–7
 23. Raymond B, Madhkoor R, Schleicher I, Uphoff C, Turnbull L, Whitchurch 
C, Rohde M, Padula M, Djordjevic S (2018) Extracellular actin is a recep-
tor for Mycoplasma hyopneumoniae. Front Cell Infect Microbiol 8:54
 24. Paes JA, Machado LDPN, dos Anjos Leal FM, de Moraes SN, Moura H, 
Barr JR, Ferreira HB (2018) Comparative proteomics of two Mycoplasma 
hyopneumoniae strains and Mycoplasma flocculare identified potential 
porcine enzootic pneumonia determinants. Virulence 9:1230–1246
 25. Ferrarini MG, Mucha SG, Parrot D, Meiffrein G, Ruggiero Bachega JF, 
Comte G, Zaha A, Sagot MF (2018) Hydrogen peroxide production and 
myo-inositol metabolism as important traits for virulence of Myco-
plasma hyopneumoniae. Mol Microbiol 108:683–696
 26. Zuo LL, Wu YM, You XX (2009) Mycoplasma lipoproteins and Toll-like 
receptors. J Zhejiang Univ Sci B 10:67–76
 27. Bai F, Ni B, Liu M, Feng Z, Xiong Q, Shao G (2015) Mycoplasma 
hyopneumoniae-derived lipid-associated membrane proteins induce 
inflammation and apoptosis in porcine peripheral blood mononuclear 
cells in vitro. Vet Microbiol 175:58–67
 28. Liu M, Du G, Liu B, Hu Y, Liu J, Jia Y, Minion FC, Shao G, Zhao R (2017) 
Cholesterol exacerbates Mycoplasma hyopneumoniae-induced apop-
tosis via stimulating proliferation and adhesion to porcine alveolar 
macrophages. Vet Microbiol 211:112–118
 29. Mitiku F, Hartley CA, Sansom FM, Coombe JE, Mansell PD, Beggs DS, 
Browning GF (2018) The major membrane nuclease MnuA degrades 
neutrophil extracellular traps induced by Mycoplasma bovis. Vet Micro-
biol 218:13–19
 30. Henthorn CR, Minion CF, Sahin O (2018) Utilization of macrophage 
extracellular trap nucleotides by Mycoplasma hyopneumoniae. Microbi-
ology 164:1394–1404
 31. Li P, Zhang Y, Li X, Zhou W, Li X, Jiang F, Wu W (2019) Mycoplasma hyo-
pneumoniae Mhp597 is a cytotoxicity, inflammation and immunosup-
pression associated nuclease. Vet Microbiol 235:53–62
 32. Raymond B, Turnbull L, Jenkins C, Madhkoor R, Schleicher I, Uphoff 
C, Whitchurch C, Rohde M, Djordjevic S (2018) Mycoplasma hyopneu-
moniae resides intracellularly within porcine epithelial cells. Sci Rep 
8:17697
 33. Grover RK, Zhu X, Nieusma T, Jones T, Boreo I, MacLeod A, Mark A, 
Niessen S, Kom H, Kong L, Assad-Garcia N, Kwon K, Chesi M, Smider V, 
Salomon D, Jelinek D, Kyle R, Pyles R, Glass J, Ward A, Wilson I, Lerner R 
(2014) A structurally distinct human mycoplasma protein that generi-
cally blocks antigen-antibody union. Science 343:656–661
 34. Arfi Y, Minder L, Di Primo C, Le-Roy A, Ebel C, Coquet L, Claverol S, 
Vashee S, Jores J, Blanchard A, Sirand-Pugnet P (2016) MIB-MIP is a 
mycoplasma system that captures and cleaves immunoglobulin G. Proc 
Natl Acad Sci U S A 113:5406–5011
 35. Pinto PM, de Carvalho MO, Alves-Junior L, Brocchi M, Schrank IS (2007) 
Molecular analysis of an integrative conjugative element, ICEH, present 
in the chromosome of different strains of Mycoplasma hyopneumoniae. 
Genet Mol Biol 30:256–263
 36. Liu W, Xiao S, Li M, Guo S, Li S, Luo R, Feng Z, Li B, Zhou Z, Shao G, Chen 
H, Fang L (2013) Comparative genomic analyses of Mycoplasma hyo-
pneumoniae pathogenic 168 Strain and its high-passaged attenuated 
strain. BMC Genomics 14:80
 37. Browning GF, Marenda MS, Noormohammadi AH, Markham PF (2011) 
The central role of lipoproteins in the pathogenesis of mycoplasmoses. 
Vet Microbiol 153:44–50
 38. Dobbs NA, Odeh AN, Sun X, Simecka JW (2009) The multifaceted role 
of T cell-mediated immunity in pathogenesis and resistance to Myco-
plasma respiratory disease. Curr Trends Immunol 10:1–19
 39. Lorenzo H, Quesada O, Assuncao P, Castro A, Rodriguez F (2006) 
Cytokine expression in porcine lungs experimentally infected 
with Mycoplasma hyopneumoniae. Vet Immunol Immunopathol 
109:199–207
 40. Muneta Y, Uenishi H, Kikuma R, Yoshihara K, Shimoji Y, Yamamoto 
R, Hamashima N, Yokomizo Y, Mori Y (2003) Porcine TLR2 and TLR6: 
identification and their involvement in Mycoplasma hyopneumoniae 
infection. J Interferon Cytokine Res 23:583–590
 41. Okusawa T, Fujita M, Nakamura J, Into T, Yasuda M, Yoshimura A, Shibata 
K (2004) Relationship between structures and biological activities of 
mycoplasmal diacylated lipopeptides and their recognition by toll-like 
receptors 2 and 6. Infect Immun 72:1657–1665
 42. Trueeb B, Braun R, Auray G, Kuhnert P, Summerfield A (2020) Differential 
innate immune responses induced by Mycoplasma hyopneumoniae and 
Mycoplasma hyorhinis in various types of antigen presenting cells. Vet 
Microbiol 240:108541
 43. Mucha S, Ferrarini M, Moraga C, De Genova A, Guyon L, Tardy F, Rome 
S, Sagot MF, Zaha A (2020) Mycoplasma hyopneumoniae J elicits an 
antioxidant response and decreases the expression of ciliary genes in 
infected swine epithelial cells. Sci Rep 10:13707
 44. Kobisch M, Blanchard B, Le Potier MF (1993) Mycoplasma hyopneumo-
niae infection in pigs: duration of the disease and resistance to reinfec-
tion. Vet Res 24:67–77
 45. Villarreal I, Meyns T, Haesebrouck F, Dewulf J, Vranckx K, Calus D, 
Pasmans F, Maes D (2011) Effect of vaccination against Mycoplasma 
hyopneumoniae on the transmission of M. hyopneumoniae under field 
conditions. Vet J 188:48–52
 46. Pieters M, Daniels J, Rovira A (2017) Comparison of sample types and 
diagnostic methods for in vivo detection of Mycoplasma hyopneumo-
niae during early stages of infection. Vet Microbiol 203:103–109
 47. Chae C, Gomes-Neto JC, Segalés J, Sibila M (2020) Diversity of 
Mycoplasma hyopneumoniae strains. In: Book Mycoplasmas in Swine. 
Chapter 8. Editors: Maes D, Sibila M, Pieters M. ISBN 978-94-6379-796-2, 
Acco Publishers, Leuven Belgium. pp. 147–161
 48. Djordjevic SP, Eamens GJ, Romalis LF, Nicholls PJ, Taylor V, Chin J (1997) 
Serum and mucosal antibody responses and protection in pigs vac-
cinated against Mycoplasma hyopneumoniae with vaccines containing 
Page 19 of 20Maes et al. Vet Res           (2021) 52:67  
a denatured membrane antigen pool and adjuvant. Aust Vet J 
75:504–511
 49. Thacker EL, Thacker BJ, Boettcher TB, Jayappa H (1998) Comparison of 
antibody production, lymphocyte stimulation, and protection induced 
by four commercial Mycoplasma hyopneumoniae bacterins. J Swine 
Health Prod 6:107–112
 50. Thacker EL, Thacker BJ, Kuhn M, Hawkins PA, Waters WR (2000) Evalua-
tion of local and systemic immune responses induced by intramuscular 
injection of a Mycoplasma hyopneumoniae bacterin to pigs. Am J Vet 
Res 61:1384–1389
 51. Sarradell J, Andrada M, Ramirez AS, Fernandez A, Gomez-Villamandos 
JC, Jover A, Lorenzo H, Herraez P, Rodriguez F (2003) A morphologic 
and immunohistochemical study of the bronchus-associated lymphoid 
tissue of pigs naturally infected with Mycoplasma hyopneumoniae. Vet 
Pathol 40:395–404
 52. Woolley L, Fell S, Gonsalves J, Raymond B, Collins D, Kuit T, Walker M, 
Djordjevic S, Eamens G, Jenkins C (2014) Evaluation of recombinant 
Mycoplasma hyopneumoniae P97/P102 paralogs formulated with 
selected adjuvants as vaccines against mycoplasmal pneumonia in 
pigs. Vaccine 32:4333–4341
 53. Marchioro S, Maes D, Flahou B, Pasmans F, Del Pozo SR, Vranckx K, 
Melkebeek V, Cox E, Wuyts N, Haesebrouck F (2013) Local and systemic 
immune responses in pigs intramuscularly injected with an inactivated 
Mycoplasma hyopneumoniae vaccine. Vaccine 31:1305–1311
 54. Deeney AS, Maglennon GA, Chapat L, Crussard S, Jolivet E, Rycroft 
AN (2019) Mycoplasma hyopneumoniae evades phagocytic uptake by 
porcine alveolar macrophages in vitro. Vet Res 50:51
 55. Borjigin L, Shimazu T, Katayama Y, Li M, Satoh T, Watanabe K, Kitazawa H, 
Roh S, Aso H, Katoh K, Uchida T, Suda Y, Nakajo SA, M, Suzuki K, (2016) 
Immunogenic properties of Landrace pigs selected for resistance to 
mycoplasma pneumonia of swine. Anim Sci J 87:321–329
 56. Abbas A, Lichtman A, Pillai S (2016) Basic immunology: functions and 
disorders of the immune system (Abbas AK, Ed. 5th edition). St. Louis, 
Missouri, USA: Elsevier
 57. Liang SC, Long AJ, Bennett F, Whitters MJ, Karim R, Collins M, Goldman 
SJ, Dunussi-Joannopoulos K, Williams CM, Wright JF (2007) An IL-17F/A 
heterodimer protein is produced by mouse Th17 cells and induces 
airway neutrophil recruitment. J Immunol 179:7791–7799
 58. Jaffar Z, Ferrini ME, Herritt LA, Roberts K (2009) Cutting edge: lung 
mucosal Th17-mediated responses induce polymeric Ig receptor 
expression by the airway epithelium and elevate secretory IgA levels. J 
Immunol 182:4507–4511
 59. Jones HP, Simecka JW (2003) T lymphocyte responses are critical deter-
minants in the pathogenesis and resistance to mycoplasma respiratory 
disease. Front Biosci 8:930–945
 60. Maes D, Boyen F, Dellagostin O, Shao G, Haesebrouck F (2020) Vac-
cines and vaccination against Mycoplasma hyopneumoniae. In: Book 
Mycoplasmas in Swine. Chapter 11. Editors: Dominiek Maes, Marina 
Sibila, Maria Pieters. ISBN 978-94-6379-796-2, Acco Publishers, Leuven 
Belgium. pp: 207–228
 61. Park C, Jeong J, Choi K, Chae C (2016) Efficacy of a new bivalent vaccine 
of porcine circovirus type 2 and Mycoplasma hyopneumoniae (Foster-
aTM PCV MH) under experimental conditions. Vaccine 34:270–272
 62. Feng Z, Wei Y, Li G, Lu X, Wan X, Pharr G, Wang Z, Kong M, Gan Y, Bai F, 
Liu M, Xiong Q, Wu X, Shao G (2013) Development and validation of an 
attenuated Mycoplasma hyopneumoniae aerosol vaccine. Vet Microbiol 
167:417–424
 63. Feng Z, Shao G, Liu M, Wu X, Zhou Y, Gan Y (2010) Immune responses 
to the attenuated Mycoplasma hyopneumoniae 168 strain vaccine by 
intrapulmonic immunization in piglets. Agr Sci China 9:423–431
 64. Michiels A, Arsenakis I, Boyen F, Krejci R, Haesebrouck F, Maes D (2017) 
Efficacy of one dose vaccination against experimental infection with 
two Mycoplasma hyopneumoniae strains. BMC Vet Res 13:274
 65. Vranckx K, Maes D, Villarreal I, Chiers K, Pasmans F, Haesebrouck F (2012) 
Vaccination reduces macrophage infiltration in bronchus-associated 
lymphoid tissue in pigs infected with a highly virulent Mycoplasma 
hyopneumoniae strain. BMC Vet Res 8:24
 66. Maes D, Deluyker H, Verdonck M, Castryck F, Miry C, Vrijens B, Verbeke 
W, Viaene J, de Kruif A (1999) Effect of vaccination against Mycoplasma 
hyopneumoniae in pig herds with an all-in/all-out production system. 
Vaccine 17:1024–1034
 67. Goodwin RF, Hodgson RG, Whittlestone P, Woodhams RL (1969) Some 
experiments relating to artificial immunity in enzootic pneumonia of 
pigs. J Hyg (Lond) 67:465–476
 68. Martelli P, Saleri R, Cavalli V, De Angelis E, Ferrari L, Benetti M, Ferrarini 
G, Merialdi G, Borghetti P (2014) Systemic and local immune response 
in pigs intradermally and intramuscularly injected with inactivated 
Mycoplasma hyopneumoniae vaccines. Vet Microbiol 168:357–364
 69. Maes D, Segalés J, Meyns T, Sibila M, Pieters M, Haesebrouck F (2008) 
Control of Mycoplasma hyopneumoniae infections in pigs. Vet Microbiol 
126:297–309
 70. Meyns T, Dewulf J, de Kruif A, Calus D, Haesebrouck F, Maes D (2006) 
Comparison of transmission of Mycoplasma hyopneumoniae in vac-
cinated and non-vaccinated populations. Vaccine 24:7081–7086
 71. Sibila M, Nofrarias M, Lopez-Soria S, Segalés J, Valero O, Espinal A, Cal-
samiglia M (2007) Chronological study of Mycoplasma hyopneumoniae 
infection, seroconversion and associated lung lesions in vaccinated and 
non-vaccinated pigs. Vet Microbiol 122:97–107
 72. Munyaka P, Blanc F, Estelle J, Lemonnier G, Leplat JJ, Rossignol MN, Jar-
det D, Plastow G, Billon Y, Willing B, Rogel-Gaillard C (2020) Discovery of 
predictors of Mycoplasma hyopneumoniae vaccine response efficiency 
in pigs: 16S rRNA gene fecal microbiota analysis. Microorganisms 
8:1151
 73. Pieters M, Fano E, Pijoan C, Dee S (2010) An experimental model to 
evaluate Mycoplasma hyopneumoniae transmission from asymptomatic 
carriers to unvaccinated and vaccinated sentinel pigs. Can J Vet Res 
74:157–160
 74. Betlach AM, Fano E, VanderWaal K, Pieters M (2021) Effect of multiple 
vaccinations on transmission and degree of Mycoplasma hyopneumo-
niae infection in gilts. Vaccine 39:767–774
 75. Fagan P, Djordjevic S, Chin J, Eamens G, Walker M (1997) Oral immuniza-
tion of mice with attenuated Salmonella typhimurium aroA expressing 
a recombinant Mycoplasma hyopneumoniae antigen (NrdF). Infect 
Immun 65:2502–2507
 76. Chen AY, Fry S, Forbes-Faulkner J, Daggard G, Mukkur T (2006) Evalua-
tion of the immunogenicity of the P97R1 adhesin of Mycoplasma hyo-
pneumoniae as a mucosal vaccine in mice. J Med Microbiol 55:923–929
 77. Chen AY, Fry S, Forbes-Faulkner J, Daggard G, Mukkur T (2006) Compara-
tive immunogenicity of M. hyopneumoniae NrdF encoded in different 
expression systems delivered orally via attenuated S Typhimurium aroA 
in mice. Vet Microbiol 114:252–259
 78. Okamba F, Moreau E, Cheikh Saad B, Gagnon C, Massie B, Arella M 
(2007) Immune responses induced by replication-defective adenovirus 
expressing the C-terminal portion of the Mycoplasma hyopneumoniae 
P97 adhesin. Clin Vaccine Immunol 14:767–774
 79. Zou H, Liu X, Ma F, Chen P, Zhou R, He Q (2011) Attenuated Actinobacil-
lus pleuropneumoniae as a bacterial vector for expression of Myco-
plasma hyopneumoniae P36 gene. J Gene Med 13:221–229
 80. Roques E, Girard A, Gagnon C, Archambault D (2013) Antibody 
responses induced in mice immunized with recombinant adenovectors 
expressing chimeric proteins of various porcine pathogens. Vaccine 
31:2698–2704
 81. Wang Y, Wang J, Zhou M, Liu P, Zhang E, Li Y, Lin J, Feng Z (2019) Yand Q 
(2019) Mucosal and systemic immune responses induced by intranasal 
immunization of recombinant Bacillus subtilis expressing the P97R1, P46 
antigens of Mycoplasma hyopneumoniae. Biosci Rep. 39:BSR20191126
 82. Menon S, Wannemuehler M, Mahairas G, Minion FC (2002) Mycobacte-
rial ESAT-6 protein enhances mouse IFN-γ responses to Mycoplasma 
hyopneumoniae P71 protein. J Interf Cytok Res 22:807–813
 83. Conceição F, Moreira A, Dellagostin O (2006) A recombinant chimera 
composed of R1 repeat region of Mycoplasma hyopneumoniae P97 
adhesin with Escherichia coli heat-labile enterotoxin B subunit elicits 
immune response in mice. Vaccine 24:5734–5743
 84. Barate A, Cho Y, Truon Q, Hahn T (2014) Immunogenicity of IMS 1113 
plus soluble subunit and chimeric proteins containing Mycoplasma 
hyopneumoniae P97 C-terminal repeat regions. FEMS Microbiol Lett 
352:213–220
 85. Virginio V, Bandeira N, Leal F, Lancelotti M, Zaha A, Ferreira H (2017) 
Assessment of the adjuvant activity of mesoporous silica nanoparticles 
in recombinant Mycoplasma hyopneumoniae antigen vaccines. Heliyon 
3:e00225
Page 20 of 20Maes et al. Vet Res           (2021) 52:67 
 86. De Oliveira NR, Jorge S, Gomez CK, Rizzi C, Dias Pacce V, Collares F, 
Monte GL, Dellagostin O (2017) A novel chimeric protein composed 
of recombinant Mycoplasma hyopneumoniae antigens as a vaccine 
candidate evaluated in mice. Vet Microbiol 201:146–153
 87. Chen Y, Wang S, Yang W, Chen Y, Lin H, Shiuan D (2003) Expression and 
immunogenicity of Mycoplasma hyopneumoniae heat shock protein 
antigen p42 by DNA vaccination. Infect Immun 71:1155–1160
 88. Minion FC, Menon S, Mahairas G, Wannemuehler M (2003) Enhanced 
murine antigen-specific gamma interferon and immunoglobulin G2a 
responses by using mycobacterial ESAT-6 sequences in DNA vaccines. 
Infect Immun 71:2239–2243
 89. Chen AY, Fry S, Daggard G, Mukkur K (2008) Evaluation of immune 
response to recombinant potential protective antigens of Mycoplasma 
hyopneumoniae delivered as cocktail DNA and/or recombinant protein 
vaccines in mice. Vaccine 26:372–378
 90. Galli V, Simionatto S, Marchioro S, Fisch A, Gomes C, Conceição F, Del-
lagostin O (2012) Immunisation of mice with Mycoplasma hyopneumo-
niae antigens P37, P42, P46 and P95 delivered as recombinant subunit 
or DNA vaccines. Vaccine 31:135–140
 91. Virginio V, Gonschoroski T, Paes J, Schuck D, Zaha A, Ferreira H (2014) 
Immune responses elicited by Mycoplasma hyopneumoniae recombi-
nant antigens and DNA constructs with potential for use in vaccination 
against porcine enzootic pneumonia. Vaccine 44:5832–5838
 92. Stevens T, Bossie A, Sanders V, Fernandez-Botran R, Coffman R, Mos-
mann T, Vitetta E (1998) Regulation of antibody isotype secretion by 
subsets of antigen-specific helper T cells. Nature 334:255–258
 93. Fairbairn L, Kapetanovic R, Sester DP, Hume DA (2011) The mononuclear 
phagocyte system of the pig as a model for understanding human 
innate immunity and disease. J Leukoc Biol 89:855–871
 94. Fagan P, Walker M, Chin J, Eamens G, Djordjevic S (2001) Oral immuniza-
tion of swine with attenuated Salmonella typhimurium aroA SL3261 
expressing a recombinant antigen of Mycoplasma hyopneumoniae 
(NrdF) primes the immune system for a NrdF specific secretory IgA 
response in the lungs. Microb Pathog 30:101–110
 95. Shimoji Y, Oishi E, Muneta Y, Nosaka H, Mori Y (2003) Vaccine efficacy of 
the attenuated Erysipelothrix rhusiopathiae YS-19 expressing a recom-
binant protein of Mycoplasma hyopneumoniae P97 adhesin against 
mycoplasmal pneumonia of swine. Vaccine 21:532–537
 96. Ogawa Y, Oishi E, Muneta Y, Sano A, Hikono H, Shibahara T, Yagi Y, 
Shimoji Y (2009) Oral vaccination against mycoplasmal pneumonia of 
swine using a live Erysipelothrix rhusiopathiae vaccine strain as a vector. 
Vaccine 27:4543–4550
 97. Okamba F, Arella M, Music N, Jia J, Gottschalk M, Gagnon C (2010) 
Potential use of a recombinant replication-defective adenovirus vector 
carrying the C-terminal portion of the P97 adhesin protein as a vaccine 
against Mycoplasma hyopneumoniae in swine. Vaccine 28:4802–4809
 98. King K, Faulds D, Rosey E, Yancey R Jr (1997) Characterization of the 
gene encoding Mhp1 from Mycoplasma hyopneumoniae and examina-
tion of Mhp1’s vaccine potential. Vaccine 15:25–35
 99. Okada M, Asai T, Ono M, Sakano T, Sato S (2000) Protective effect of 
vaccination with culture supernate of M. hyopneumoniae against 
experimental infection in pigs. J Vet Med B 47:527–533
 100. Okada M, Asai T, Ono M, Sakano T, Sato S (2000) Cytological and 
immunological changes in bronchoalveolar lavage fluid and histologi-
cal observation of lung lesions in pigs immunized with Mycoplasma 
hyopneumoniae inactivated vaccine prepared from broth culture 
supernate. Vaccine 18:2825–2831
 101. Chen J, Liao C, Mao S, Weng C (2001) A recombinant chimera com-
posed of repeat region RR1 of Mycoplasma hyopneumoniae adhesin 
with Pseudomonas exotoxin: in vivo evaluation of specific IgG response 
in mice and pigs. Vet Microbiol 80:347–357
 102. Lee SH, Lee S, Chae C, Ryu D-Y (2014) A recombinant chimera com-
prising the R1 and R2 repeat regions of M. hyopneumoniae P97 and 
the N-terminal region of A. pleuropneumoniae ApxIII elicits immune 
responses. BMC Vet Res. 10:43
 103. Lin J, Pan M, Liao C, Weng C (2002) In vivo and in vitro comparisons of 
spray-drying and solvent-evaporation preparation of microencapsu-
lated Mycoplasma hyopneumoniae for use as an orally administered 
vaccine for pigs. Am J Vet Res 63:1118–1123
 104. Lin J, Weng C, Liao C, Yeh K, Pan M (2003) Protective effects of oral 
microencapsulated Mycoplasma hyopneumoniae vaccine prepared by 
co-spray drying method. J Vet Med Sci 65:69–74
 105. Matthijs A, Auray G, Jakob V, García-Nicolás O, Braun R, Keller I, Brug-
gman R, Devriendt B, Boyen F, Guzman C, Michiels A, Haesebrouck F, 
Collin N, Barnier-Quer C, Maes D, Summerfield A (2019) System immu-
nology characterization of novel vaccine formulations for Mycoplasma 
hyopneumoniae bacterins. Front Immunol 10:1087
 106. Matthijs A, Auray G, Boyen F, Michiels A, Garcia-Nicolas O, Barut GT, 
Barut G, Barnier-Quer C, Jakob V, Collin N, Devriendt B, Summerfield A, 
Haesebrouck F, Maes D (2019) Efficacy of three innovative bacterin vac-
cines against experimental infection with Mycoplasma hyopneumoniae. 
Vet Res 50:91
 107. Meens J, Bolotin V, Frank R, Böhmer J, Gerlach GF (2010) Characteriza-
tion of a highly immunogenic Mycoplasma hyopneumoniae lipoprotein 
Mhp366 identified by peptide-spot array. Vet Microbiol 142:293–302
 108. Pendarvis K, Padula MP, Tacchi JL, Petersen AC, Djordjevic SP, Burgess SC, 
Minion FC (2014) Proteogenomic mapping of Mycoplasma hyopneumo-
niae virulent strain 232. BMC Genomics 15:576
 109. Neutra MR, Kozlowski PA (2006) Mucosal vaccines: the promise and the 
challenge. Nat Rev Immunol 6:148–158
 110. Aoshi T (2017) Modes of action for mucosal vaccine adjuvants. Viral 
Immunol 30:463–470
 111. Figueras Gourgues S, Fano E, Alegre Sabaté A, López Grasa E, Hernán-
dez Caravaca I, García Vázquez FA, Rodríguez Vega V, Garcia-Morante 
B (2020) Assessment of nebulization technology for gilt exposure to 
Mycoplasma hyopneumoniae as an acclimation strategy. J Swine Health 
Prod 28:294–301
 112. Wilson HL, Obradovic MR (2015) Evidence for a common mucosal 
immune system in the pig. Mol Immunol 66:22–34
 113. Fu T, Ulmer JB, Caufield MJ, Deck RR, Friedman A, Wang S, Liu X, Don-
nelly JJ, Liu MA (1997) Priming of cytotoxic T lymphocytes by DNA 
vaccines. Requirement for professional antigen presenting cells and 
evidences for antigen transfer from myocytes. Mol Med 3:362–371
 114. Bastola R, Noh G, Keum T, Bashyal S, Seo JE, Choi J, Oh Y, Cho Y, Lee S 
(2017) Vaccine adjuvants: smart components to boost the immune 
system. Arch Pharm Res 40:1238–1248
 115. Villarreal I, Maes D, Meyns T, Gebruers F, Calus D, Pasmans F, Haeseb-
rouck F (2009) Infection with a low virulent Mycoplasma hyopneumo-
niae isolate does not protect piglets against subsequent infection with 
a highly virulent M. hyopneumoniae isolate. Vaccine 27:1875–1879
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in pub-
lished maps and institutional affiliations.
